Skip to content

The effect of Huiyang Shengji Ointment on lymphatic angiogenesis in patients with DFU by regulating the pyrogenic pathway of refractory wound

The effect of Huiyang Shengji Ointment on lymphatic angiogenesis in patients with DFU by regulating the pyrogenic pathway of refractory wound

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000487
Enrollment
Unknown
Registered
2024-09-26
Start date
2024-09-05
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic foot ulcer

Interventions

HYSJ group:Huiyang Shengji unguent
Control group:Basic fibroblast growth factor

Sponsors

Beijing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old; (2) Met the clinical diagnostic criteria for diabetic foot, and Wagner grade was 1-3 at the time of enrollment; (3) Wounds with diabetes mellitus and foot ulcers that have not healed for more than 4 weeks and have no obvious healing trend (Yin syndrome); (4) The color of the wound is dark, the pus is thin, the muscle growth is slow, and the wound is difficult to converge. (5) No external treatment drugs were used on the wound in the first month before enrollment.

Exclusion criteria

Exclusion criteria: (1) There are multiple ulcerative lesions or deep ulcers on the limb of the intended test side, accompanied by wound sinus or fistula, or surgical treatment is required; (2) Patients with other infectious diseases, serious primary diseases, and mental disorders; (3) Patients with severe cardiac function, liver function and renal function (NYHA grade =3, alanine aminotransferase > 2.5 times of normal control value, blood creatinine > 1.5 times of normal control value), or other organ function abnormalities; (4) Allergic or allergic to any component of the test drug; (5) Any other factors that the investigator considers to be potentially risky or disturbing to the subject.

Design outcomes

Primary

MeasureTime frame
Lymphoendothelial markers;

Secondary

MeasureTime frame
Pyroxacin executive protein;interleukin;

Countries

China

Contacts

Public ContactXu Xuying

Beijing Hospital of Traditional Chinese Medicine Capital Medical University

xxying7341@126.com13121515220

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026